Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2451-2460

  Costello, Daniel J ^a,b   O'Keeffe, Gerard W ^a   Hurley, Fiona M ^a   Sullivan, Aideen M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Dopamine; Growth differentiation factor 5; Neurodegeneration; Neurotrophic factor; Parkinson's disease

Indexed keywords

GDF5 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR 5; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE;

ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CHO CELL; CULTURE TECHNIQUE; CYTOLOGY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; HAMSTER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MESENCEPHALON; METABOLISM; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PATHOLOGY; PRENATAL DEVELOPMENT; RAT; SPRAGUE DAWLEY RAT; TRANSPLANTATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL SURVIVAL; CHO CELLS; CRICETINAE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GROWTH DIFFERENTIATION FACTOR 5; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; MESENCEPHALON; MULTIVARIATE ANALYSIS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84866747289     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01562.x     Document Type: Article

References (45)

1. Toulouse A, Sullivan AM. Progress in Parkinson's disease-where do we stand? Prog Neurobiol. 2008; 85: 376-92.
2. Bjorklund A, Dunnett SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2003; 2: 437-45.
3. Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci. 2001; 2: 365-9.
4. Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 2001; 60: 741-52.
5. Lindvall O, Hagell P. Cell therapy and transplantation in Parkinson's disease. Clin Chem Lab Med. 2001; 39: 356-61.
6. Sayles M, Jain M, Barker RA. The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl Immunol. 2004; 12: 321-42.
7. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res. 2010; 184: 265-94.
8. Olanow CW, Kordower JH, Lang AE, Obeso JA. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009; 66: 591-6.
9. Bjorklund A. Cell therapy for Parkinson's disease: problems and prospects. Novartis Found Symp. 2005; 265: 174-86.
10. Brundin P, Pogarell O, Hagell P, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000; 123: 1380-90.
11. Deierborg T, Soulet D, Roybon L, et al. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol. 2008; 85: 407-32.
12. O'Neill MJ, Messenger MJ, Lakics V, et al. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. Int Rev Neurobiol. 2007; 77: 179-217.
13. Sortwell CE. Strategies for the augmentation of grafted dopamine neuron survival. Front Biosci. 2003; 8: 522-32.
14. Aron L, Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci. 2010; 34: 88-100.
15. Sullivan AM, Toulouse A. Neurotrophic factors for the treatment of Parkinson's disease. Cytokine Growth Factor Rev. 2011; 22: 157-65.
16. Storm EE, Huynh TV, Copeland NG, et al. Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature. 1994; 368: 639-43.
17. O'Keeffe GW, Hanke M, Pohl J, Sullivan AM. Expression of growth differentiation factor-5 in the developing and adult rat brain. Brain Res Dev Brain Res. 2004; 151: 199-202.
18. Gates MA, Torres EM, White A, et al. Re-examining the ontogeny of substantia nigra dopamine neurons. Eur J Neurosci. 2006; 23: 1384-90.
19. Marti J, Wills KV, Ghetti B, Bayer SA. A combined immunohistochemical and autoradiographic method to detect midbrain dopaminergic neurons and determine their time of origin. Brain Res Brain Res Protoc. 2002; 9: 197-205.
20. O'Keeffe GW, Dockery P, Sullivan AM. Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurons in vitro. J Neurocytol. 2004; 33: 479-88.
21. O'Sullivan DB, Harrison PT, Sullivan AM. Effects of GDF5 overexpression on embryonic rat dopaminergic neurons in vitro and in vivo. J Neural Transm. 2010; 117: 559-72.
22. Wood TK, McDermott KW, Sullivan AM. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J Neurosci Res. 2005; 80: 759-66.
23. Krieglstein K, Suter-Crazzolara C, Hötten G, et al. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J Neurosci Res. 1995; 42: 724-32.
24. Lingor P, Unsicker K, Krieglstein K. Midbrain dopaminergic neurons are protected from radical induced damage by GDF-5 application. J Neural Transm. 1999; 106: 139-44.
25. Hurley FM, Costello DJ, Sullivan AM. Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Exp Neurol. 2004; 185: 281-9.
26. Sullivan AM, Opacka-Juffry J, Hotten G, et al. Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurons in a rat model of Parkinson's disease. Neurosci Lett. 1997; 233: 73-6.
27. Sullivan AM, Opacka-Juffry J, Pohl J, Blunt SB. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res. 1999; 818: 176-9.
28. Sullivan AM, Pohl J, Blunt SB. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci. 1998; 10: 3681-8.
29. Pellegrino LJ, Pellegrino AS, Cushman AJ. A Stereotaxic Atlas of the Rat Brain. New York: Plenum Press; 1979.
30. Mayhew TM. A review of recent advances in stereology for quantifying neural structure. J Neurocytol. 1992; 21: 313-28.
31. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th edn. San Diego: Academic Press; 1988.
32. Duan WM, Widner H, Brundin P. Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. Exp Brain Res. 1995; 104: 227-42.
33. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970; 24: 485-93.
34. Kordower JH, Styren S, Clarke M, et al. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 1997; 6: 213-9.
35. Ichitani Y, Okamura H, Matsumoto Y, et al. Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res. 1991; 549: 350-3.
36. Ichitani Y, Okamura H, Nakahara D, et al. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp Neurol. 1994; 130: 269-78.
37. Przedborski S, Levivier M, Jiang H, et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 1995; 67: 631-47.
38. Rosenblad C, Kirik D, Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol. 2000; 161: 503-16.
39. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 1994; 59: 401-15.
40. Akerud P, Canals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci. 2001; 21: 8108-18.
41. Behrstock S, Ebert A, McHugh J, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to par-kinsonian rodents and aged primates. Gene Ther. 2006; 13: 379-88.
42. Wu J, Yu W, Chen Y, et al. Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model. Neurochem Res. 2010; 35: 495-502.
43. Ostenfeld T, Tai Y-T, Martin P, et al. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res. 2002; 69: 955-65.
44. Nakao N, Frodl EM, Duan WM, et al. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA. 1994; 91: 12408-12.
45. Dyson SC, Barker RA. Cell-based therapies for Parkinson's disease. Expert Rev Neurother. 2011; 11: 831-44.